News

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial...

A Deal to Fix the Broken Antibiotic Market?

The market for new antibiotics is effectively failing. No novel class of drugs for the most virulent and persistent infections, those caused by Gram negative bacteria, has entered the clinic for over 50 years, and the drugs we have are steadily, i...

Cytox appoints Ian Gilham as new Chairman of the Board

8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gil...

UKI2S, Catapult Ventures and Jonathan Milner invest £500k in Gene Modulation Newcomer Pencil Biosciences

11th December, 2019, Alderley Park: UK Innovation & Science Seed Fund (UKI2S), Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation compa...

The AMR Centre's Dr Peter Jackson in Laboratory News

Moving from Push to Pull Nothing less than an entirely new model of drug development is needed if we are to create new antibiotics says Dr Peter Jackson. And it’s something NICE are finally taking seriously as they set about developing a ne...

From our portfolio

Rinicare

Digital Healthcare Technology

viewview our portfolio

Our Team

Nick Wright

CEO

view complete team

Contact us

Alderley Park
Alderley Edge
Cheshire
SK10 4TG

Tel: 01625 344300

email